Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Cellectar Biosciences, Inc.
Children's Oncology Group
Essen Biotech
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Australian & New Zealand Children's Haematology/Oncology Group
ITM Solucin GmbH
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Cancer Research UK
Turning Point Therapeutics, Inc.
St. Jude Children's Research Hospital
Incyte Corporation
Virginia Commonwealth University
Institut Curie
National Cancer Institute (NCI)
Washington University School of Medicine
Incyte Corporation
Barbara Ann Karmanos Cancer Institute
Rigshospitalet, Denmark
Miltenyi Biomedicine GmbH
Cedars-Sinai Medical Center
BPGbio
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Pfizer
Children's Oncology Group
Children's Oncology Group
Dana-Farber Cancer Institute
EMD Serono
Cedars-Sinai Medical Center
University of Virginia
Seattle Children's Hospital
University Hospital, Basel, Switzerland
Celgene
Bayer
National Cancer Institute (NCI)
Children's Hospital Los Angeles
City of Hope Medical Center
OHSU Knight Cancer Institute
Eastern Cooperative Oncology Group
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Children's Hospital Medical Center, Cincinnati
National Institute of Allergy and Infectious Diseases (NIAID)
Celgene
University College, London
Northwestern University